(Q39033713)

8 September 2017

title

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? (English)

1 reference

8 September 2017

1 reference

Tawee Tanvetyanon

1

1 reference

8 September 2017

Jhanelle E Gray

series ordinal

2

1 reference

8 September 2017

Scott J Antonia

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

9 January 2017

1 reference

Expert Opinion on Biological Therapy

8 September 2017

published in

1 reference

8 September 2017

volume

17

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

305-312

1 reference

Current developments in cancer vaccines and cellular immunotherapy

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Biomarkers for Immunotherapy: Current Developments and Challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1280454

10.1080/14712598.2017.1280454

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference